Objective To evaluate the efficacy and side effects of Nimotuzumab in combination with three dimensional conformal radiation therapy for nasopharyngeal carcinoma. Methods 15 patients with nasopharyngeal carcinoma from December 2008 to December 2011 were enrolled. Patients were treated with concurrent chemotherapy of Nimotuzumab combined with Cisplatin when taking three dimensional conformal radiation therapy. The radical radiotherapy dose was 60-70 Gy every 6-7 weeks, once 2 Gy, 5 times a week; patients were given DDP solution (Cisplatin 20 mg/m2, d1-4) and two cycles for systemic chemotherapy at the same time, every 3 weeks was as a course. Nimotuzumab was added at a dose of 100 mg at the beginning of radiotherapy, once a week, for 6-7 times. Results 15 patients received a total of 92 times of Nimotuzumab (median 6.1 times). There was 1 case of complete response (CR), 1 case of partial response (PR) and 13 cases of stable disease (SD), the disease control rate (CR+PR+SD) was 100%. With a median follow-up of 13.5 months, the median progression-free survival was 7.3 months and the median overall-survival was 13.8 months. The most common toxicities included neutropenia, oropharyngeal mucositis, nausea and vomiting, dermatitis. The most common Nimotuzumab related side effect was fever, which didn't disturb the therapy. Conclusion Nimotuzumab combined with three dimensional conformal radiation therapy has a good effect and less side effects, which is an effective therapy for nasopharyngeal carcinoma.%目的 观察尼妥珠单抗联合三维适形同步放化疗对鼻咽癌的疗效和不良反应.方法 2008年12月～2011年12月共收集鼻咽癌患者15例,患者在接受三维适形放疗的同时给予尼妥珠单抗联合顺铂方案同步化疗,放疗根治剂量为60～70 Gy/6～7周,2 Gy/次,5次/周;放疗期间给予DDP方案(顺铂20 mg/m2,d1～4)同期全身化疗2个疗程,每3周为1个疗程.放疗第1天开始用尼妥珠单抗100 mg,每周1次,共6～7次.结果 15例患者共接受92次的尼妥珠单抗治疗,平均6.1次.完全缓解(CR)1例,部分缓解(PR)1例,稳定(SD)13例,控制率DCR(CR+PR+SD)为100%.平均随访13.5个月,中位无疾病进展时间7.3个月,中位生存时间13.8个月.治疗过程中不良反应主要为同期放化疗过程中产生的骨髓抑制、口腔黏膜炎、消化道反应、皮肤反应等.与尼妥珠单抗治疗相关的不良反应主要为发热.以上不良反应均未影响治疗进程.结论 尼妥珠单抗联合三维适形同步放化疗治疗鼻咽癌患者疗效尚可,药物不良反应少,是鼻咽癌良好的治疗方法.
展开▼
